Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.03 USD | +1.77% | +6.05% | +9.02% |
05-09 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-08 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.02% | 19.77M | |
+5.66% | 111B | |
+11.23% | 105B | |
-12.15% | 22.34B | |
-2.68% | 21.93B | |
-5.61% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- Ladenburn Thalmann Starts NeuroBo Pharmaceuticals at Buy With $6 Price Target